Skip Navigation
Skip to contents

Clin Mol Hepatol.  2026 Jan;32(1):91-126. 10.3350/cmh.2025.0476.

Harnessing the microbiome: unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies

Affiliations
  • 1Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong
  • 2Research Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong

Abstract

The gut microbiota significantly influences hepatobiliary cancer therapeutics. Growing evidence indicates that shifts in the gut microbial ecosystem are hallmarks of hepatocellular carcinoma and cholangiocarcinoma, strongly correlating with tumor development, therapeutic resistance, and patient survival. The composition of gut microbiota has emerged as a biomarker associated with treatment outcomes across various modalities, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Beneficial bacterial communities enhance antitumor immunity, while pathogenic taxa are linked to reduced therapeutic efficacy. Multi-omics analyses have identified microbial metabolite signatures, such as short-chain fatty acids and bile acids, as potential targets for boosting antitumor responses. This review highlights the transformative potential of leveraging the gut microbiota to enhance precision oncology in hepatobiliary cancer. Future directions should prioritize personalized microbiota modulation approaches, combinatorial therapies targeting gut-liver axis crosstalk, and large-scale validation of microbial biomarkers across diverse populations.

Keyword

Gastrointestinal microbiome; Hepatobiliary cancer; Immunosuppression therapy; Therapeutic resistance
Full Text Links
  • CMH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2026 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr